{"publication_id":"98a3a091-c5b2-412b-a3c6-744963f23cb2","traces":[{"claim_id":"claim_1","claim":"The cited A/B receipts support a specific working claim: Gastrointestinal adverse events were more frequent with semaglutide (82.8%) vs placebo (63.2%); Gastrointestinal events were reported in 49.1% of participants who continued subcutaneous semaglutide vs 26.1% with placebo. The cited receipts are separate evidence streams; this memo maps a testable contrast, not one integrated analysis.","candidate_sources":[{"study":"Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial","doi":null,"url":null},{"study":"Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity The STEP 4 Randomized Clinical Trial","doi":null,"url":null},{"study":"Efficacy and safety of once‐weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus—A systematic review and meta‐analysis of randomized controlled trials","doi":"10.1111/obr.13792","url":null},{"study":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","doi":"10.1038/s41591-022-02026-4","url":null},{"study":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","doi":"10.1038/s41591-024-03015-5","url":null}]},{"claim_id":"claim_2","claim":"Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.","candidate_sources":[{"study":"Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial","doi":null,"url":null},{"study":"Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity The STEP 4 Randomized Clinical Trial","doi":null,"url":null},{"study":"Efficacy and safety of once‐weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus—A systematic review and meta‐analysis of randomized controlled trials","doi":"10.1111/obr.13792","url":null},{"study":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","doi":"10.1038/s41591-022-02026-4","url":null},{"study":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","doi":"10.1038/s41591-024-03015-5","url":null}]},{"claim_id":"claim_3","claim":"Bounded research question:** Does the cited receipt bundle still support this bounded claim when population, endpoint, comparator, and time window are aligned?","candidate_sources":[{"study":"Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial","doi":null,"url":null},{"study":"Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity The STEP 4 Randomized Clinical Trial","doi":null,"url":null},{"study":"Efficacy and safety of once‐weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus—A systematic review and meta‐analysis of randomized controlled trials","doi":"10.1111/obr.13792","url":null},{"study":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","doi":"10.1038/s41591-022-02026-4","url":null},{"study":"Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial","doi":"10.1038/s41591-024-03015-5","url":null}]}]}